Next Article in Journal
The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML)
Next Article in Special Issue
The Role of Cyclic Nucleotide Signaling Pathways in Cancer: Targets for Prevention and Treatment
Previous Article in Journal
RGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone Metastasis
Previous Article in Special Issue
Preclinical Cancer Chemoprevention Studies Using Animal Model of Inflammation-Associated Colorectal Carcinogenesis
Article Menu

Export Article

Open AccessReview
Cancers 2012, 4(4), 1146-1160;

Chemoprevention of Breast Cancer: The Paradox of Evidence versus Advocacy Inaction

Division of Surgical Oncology, Texas Tech University Health Sciences Center, Amarillo Breast Center of Excellence, 1400 Coulter, Amarillo, TX 79106, USA
Division of General Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Author to whom correspondence should be addressed.
Received: 31 July 2012 / Revised: 23 September 2012 / Accepted: 19 October 2012 / Published: 29 October 2012
(This article belongs to the Special Issue Advances in Cancer Chemoprevention)
Full-Text   |   PDF [506 KB, uploaded 29 October 2012]


Women who are at high risk of breast cancer can be offered chemoprevention. Chemoprevention strategies have expanded over the past decade and include selective receptor modulator inhibitors and aromatase inhibitors. Physicians are expected to provide individualized risk assessments to identify high risk women who may be eligible for chemoprevention. It is prudent that physicians utilize a shared decision approach when counseling high risk women about their preventive options. Barriers and misperceptions however exist with patient and physician acceptance of chemoprevention and continue to impede uptake of chemoprevention as a strategy to reduce breast cancer risk. Programs to increase awareness and elucidate the barriers are critical for women to engage in cancer prevention and promote chemoprevention adherence. View Full-Text
Keywords: aromatase inhibitors; chemoprevention; exemestane; raloxifene; SERMs; tamoxifen aromatase inhibitors; chemoprevention; exemestane; raloxifene; SERMs; tamoxifen
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Layeequr Rahman, R.; Pruthi, S. Chemoprevention of Breast Cancer: The Paradox of Evidence versus Advocacy Inaction. Cancers 2012, 4, 1146-1160.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top